clofibrate has been researched along with bezafibrate in 126 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 70 (55.56) | 18.7374 |
1990's | 35 (27.78) | 18.2507 |
2000's | 13 (10.32) | 29.6817 |
2010's | 7 (5.56) | 24.3611 |
2020's | 1 (0.79) | 2.80 |
Authors | Studies |
---|---|
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
Henke, BR | 1 |
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF | 1 |
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
Bolzano, K; Krempler, F; Schellenberg, B; Schlierf, G | 1 |
Imanaka, T; Itoga, H; Okawa, S; Suga, T; Watanabe, T | 1 |
Dorić, M; Gligora, M | 1 |
Iida, T; Suga, T; Tamura, H; Watanabe, T | 2 |
Eacho, PI; Foxworthy, PS; Hoover, DM; White, SL | 1 |
Schwandt, P | 1 |
Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
Hirst, DG | 1 |
Bass, NM; Brandes, R; Kaikaus, RM; Lysenko, N; Ockner, RK | 1 |
Abraham, DJ; Mehanna, AS | 1 |
Hirst, DG; Wood, PJ | 1 |
Green, KG; Heady, A; Oliver, MF | 1 |
Angelin, B; Einarsson, K; Ståhlberg, D | 1 |
Arad, R; Bar-Tana, J; Brandes, R | 1 |
Agius, L; Alberti, KG; Gerondaes, P | 2 |
Krause, BR; Newton, RS | 1 |
Bonner, FW; Eason, CT; Howells, DD; Pattison, A; Spencer, AJ | 1 |
Palmer, RH | 1 |
Hunninghake, DB; Peters, JR | 1 |
Grundy, SM; Vega, GL | 1 |
Kurasawa, T; Yamamoto, A; Yokoyama, S | 1 |
Hirst, DG; Schwartz, HC; Wood, PJ | 1 |
Postiglione, A; Riccardi, G; Saldalamacchia, G | 1 |
Branzoli, U; Carganico, G; Chiari, A; Cozzi, P; Lovisolo, PP; Severino, D | 1 |
Lang, PD; Oster, P; Schlierf, G; Vollmar, J | 1 |
Lang, PD; Mordasini, R; Oster, P; Schlierf, G; Vollmar, J | 1 |
Perutz, MF; Poyart, C | 1 |
Boag, DE; Lorimer, AR; Packard, CJ; Shepherd, J; Stewart, JM | 1 |
Honková, M; Kunesová, M; Mares, P; Skorepa, J; Zeman, M | 1 |
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD | 1 |
Harvengt, C; Heller, F | 1 |
Rüth, E; Vollmar, J | 1 |
Fischer, H; Oster, P; Roche, A; Schellenberg, B; Schlierf, G; Stiehl, A; Vollmar, J | 1 |
Keller, M; Lang, PD; Middelhoff, G; Mordasini, R; Oster, P; Riesen, W | 1 |
Holler, HD; Janka, HU; Mehnert, H; Standl, A | 1 |
Dorda, W; Kostner, GM; Mühlhauser, I; Prager, R; Schernthaner, G; Zechner, R | 1 |
Lang, PD; Vollmar, J | 1 |
Day, AJ; Hudson, K; Mojumder, S | 1 |
Kurlat, MI; Neuman, J; Neuman, MP | 1 |
Djaja, S; Machalke, K; Richter, E | 1 |
Fahimi, HD; Hartig, F; Ozel, M; Reinicke, A; Stegmeier, K; Sujatta, M; Yokota, S | 1 |
Lageder, H | 1 |
Abshagen, U; Marinow, J; Spörl-Radun, S | 1 |
Boberg, J; Gustafsson, IB; Hellsing, K; Ledermann, H; Lithell, H; Ostlund-Lindqvist, AM; Vessby, B | 1 |
Kokot, F; Szczechowska, E | 1 |
Dick, TB; Ledermann, HM; Marples, J; Whittington, J | 1 |
Grützmacher, P; Lang, W; Scheuermann, E | 1 |
Day, AJ; Hudson, K; Marceglia, A | 1 |
Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG | 1 |
Drosner, M; Janetschek, P; Schwandt, P; Weisweiler, P | 1 |
Lazarow, PB; Leroy-Houyet, MA; Shio, H | 1 |
Lang, PD; Mertz, DP; Vollmar, J | 1 |
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
Ledermann, H; Lithell, H; Vessby, B | 1 |
Heidland, A; Hörl, M; Hörl, WH | 1 |
Anderson, P; Norbeck, HE | 2 |
Fringes, B; Riede, UN; von Deimling, O | 1 |
Day, AJ; Hudson, K | 1 |
Braeuning, C; Middelhoff, G; Schlierf, G; Wirth, A | 1 |
Kłosiewicz-Latoszek, L; Naruszewicz, M; Nowicka, G; Szostak, WB | 1 |
Hofmann, H; Holler, HD; Stratmann, FW | 1 |
Bertuletti, R; Carini, M; Maffei, FR; Tofanetti, O | 1 |
Schwandt, P; Weisweiler, P | 1 |
Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG | 2 |
Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R | 1 |
Seidel, D; Walli, AK | 1 |
Bock, KD; Heidemann, H | 1 |
Kjellin, KG; Ledermann, H; Noring, L | 1 |
Bruneder, H; Klein, HJ | 1 |
Bock, KD | 1 |
Kaufmann, B; Ledermann, H | 1 |
Carini, M; Facino, RM | 1 |
Abshagen, U; Kaufmann, B; Kösters, W; Lang, PD | 1 |
Bachmann, C; Fragiacomo, C; Noseda, G; Weidmann, P | 1 |
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W | 1 |
Mertz, DP | 1 |
Adzet, T; Alegret, M; Cerqueda, E; Ferrando, R; Laguna, JC; Merlos, M; Sánchez, RM; Vázquez, M | 1 |
Shand, JH; West, DW | 3 |
Dujovne, CA; Lozada, A | 1 |
Gibson, GG; Howes, D; Kass, GE; Orrenius, S; Shackleton, GL; Sharma, RK | 1 |
Adzet, T; Alegret, M; Ferrando, R; Laguna, JC; Merlos, M; Vázquez, M | 1 |
Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
Kato, N; Sasago, S; Satoh, A; Takahashi, S | 1 |
Amiconi, G; Ascenzi, P; Bertollini, A; Coletta, M; Desideri, A; Giardina, B; Polizio, F; Santucci, R; Scatena, R | 1 |
Bismuth, J; Bonne, J; Gharbi-Chihi, J; Teboul, M; Torresani, J | 1 |
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM | 1 |
Adzet, T; Alegret, M; Laguna, JC; Merlos, M; Muñoz, S; Vázquez, M | 1 |
Adzet, T; Alegret, M; Laguna, JC; López, M; Merlos, M; Rodríguez, C; Vázquez, M | 1 |
Galloway, SM; Johnson, TE; Ledwith, BJ; Manam, S; Nichols, WW; Pauley, CJ; Wagner, LK | 1 |
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME | 1 |
Adzet, T; Laguna, JC; Merlos, M; Vázquez, M | 1 |
Diemer, S; Eberlein-König, B; Przybilla, B | 1 |
Amacher, DE; Beck, R; Kenny, CV; Schomaker, SJ | 1 |
Andersen, O; Dehli, A; Gjøen, T; Ostlund Farrants, AK; Ruyter, B; Thomassen, MS | 1 |
de Wit, EC; Huisman, H; Kaptein, A; Neele, DM; Princen, HM | 1 |
Wallace, KB; Zhou, S | 1 |
Brun, S; Carmona, MC; Giralt, M; Iglesias, R; Mampel, T; Villarroya, F; Viñas, O | 1 |
Arakawa, M; Hasegawa, H; Ishikawa, H; Ito, S; Murasawa, A; Nakano, M; Nakazono, K; Nozawa, S; Onuki, K; Tohyama, C | 1 |
Tada, N | 1 |
Ascenzi, P; Coletta, M; Fasano, M; Mattu, M; Vannin, A | 1 |
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
Agellon, LB; Gbaguidi, GF | 1 |
Dobordzhginidze, LM; Gratsianskiĭ, NA | 1 |
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
Chinetti, G; Fontaine, C; Fruchart, JC; Robillard, R; Staels, B | 1 |
Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kawamura, T; Matsumura, K; Matsushita, T; Miyamoto, L; Nakamoto, A; Nemoto, H; Taoka, C; Tsuchiya, K | 1 |
Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
Jiao, S; Li, Q; Pan, M; Qu, J; Reinach, PS; Srinivasalu, N; Yan, J; Yang, Y; Zhou, X | 1 |
de Haas, R; Frambach, SJCM; Russel, FGM; Schirris, TJJ; Smeitink, JAM; van de Wal, MAE; van den Broek, PHH | 1 |
11 review(s) available for clofibrate and bezafibrate
Article | Year |
---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids | 1987 |
Fibric acids: effects on lipids and lipoprotein metabolism.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides | 1987 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
[Overviews of fibrate].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
[Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].
Topics: Bezafibrate; Clofibrate; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Randomized Controlled Trials as Topic | 2004 |
Fibrates.
Topics: Animals; Atherosclerosis; Bezafibrate; Cholesterol; Clofibrate; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; PPAR alpha | 2005 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
17 trial(s) available for clofibrate and bezafibrate
Article | Year |
---|---|
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Hypolipidemic effects of bezafibrate: studies in Italy.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipids; Lipoproteins; Random Allocation | 1986 |
Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate.
Topics: Adult; Aged; Bezafibrate; Circadian Rhythm; Clofibrate; Dietary Fats; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Triglycerides | 1986 |
Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
Topics: Adult; Bezafibrate; Cholesterol; Circadian Rhythm; Clofibrate; Half-Life; Humans; Lipids; Lipoproteins; Male; Triglycerides | 1985 |
[Therapeutic effects of bezafibrate in hyperlipidemia].
Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged | 1983 |
[The effect of bezafibrate on biliary lipids (author's transl)].
Topics: Adult; Bezafibrate; Bile; Clofibrate; Clofibric Acid; Drug Evaluation; Humans; Hyperlipoproteinemias; Lipids | 1980 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Glyburide; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Patient Compliance | 1982 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Diabetes Mellitus; Female; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Phosphatidylcholine-Sterol O-Acyltransferase | 1982 |
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Theophylline; Xanthinol Niacinate | 1982 |
[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; Placebos; Triglycerides | 1980 |
Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
Topics: Administration, Oral; Adult; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Half-Life; Humans; Hypolipidemic Agents; Kinetics | 1980 |
[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation; Triglycerides | 1981 |
Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Urea | 1981 |
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Triglycerides | 1981 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Female; Galactans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Mannans; Middle Aged; Plant Gums; Polysaccharides | 1982 |
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Phospholipids; Placebos; Triglycerides | 1981 |
99 other study(ies) available for clofibrate and bezafibrate
Article | Year |
---|---|
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides | 2009 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged | 1979 |
Involvement of calmodulin- and protein kinase C-related mechanism in an induction process of peroxisomal fatty acid oxidation-related enzymes by hypolipidemic peroxisome proliferators.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bezafibrate; Body Weight; Calmodulin; Catalase; Cells, Cultured; Clofibrate; Diethylhexyl Phthalate; Electrophoresis, Polyacrylamide Gel; Isoquinolines; Kinetics; Liver; Male; Membrane Proteins; Microbodies; Molecular Weight; Organ Size; Oxidation-Reduction; Piperazines; Protein Kinase C; Pyrimidines; Rats; Rats, Inbred Strains; Reference Values; Trifluoperazine | 1992 |
Further possibilities of using aryloxycarbonic acid derivatives in clinical practice.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Connective Tissue Diseases; Fenofibrate; Humans; Lymphocyte Activation; Phytohemagglutinins | 1991 |
Lack of induction of hepatic DNA damage on long-term administration of peroxisome proliferators in male F-344 rats.
Topics: Animals; Bezafibrate; Clofibrate; Diethylhexyl Phthalate; DNA Damage; DNA, Single-Stranded; Lipid Peroxidation; Liver; Male; Oxidation-Reduction; Rats; Rats, Inbred F344 | 1991 |
Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
Topics: Acetophenones; Animals; Autacoids; Azoles; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Dexamethasone; Dogs; Dose-Response Relationship, Drug; Female; Fibric Acids; Glucagon; Hypolipidemic Agents; In Vitro Techniques; Liver; Male; Microbodies; Microscopy, Electron; NAD; Oxidation-Reduction; Rats; Tetrazoles; Tyrosine Transaminase | 1990 |
Fibrates and triglyceride metabolism.
Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
Tumour radiosensitization by clofibrate and its analogs: possible mechanisms.
Topics: Animals; Bezafibrate; Clofibrate; Combined Modality Therapy; Etanidazole; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Regional Blood Flow | 1990 |
Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation.
Topics: Animals; Bezafibrate; Carrier Proteins; Cell Division; Cells, Cultured; Clofibrate; Epoxy Compounds; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Liver; Male; Microbodies; Neoplasm Proteins; Nerve Tissue Proteins; Oxidation-Reduction; Palmitoyl Coenzyme A; Rats; Rats, Inbred Strains | 1990 |
Comparison of crystal and solution hemoglobin binding of selected antigelling agents and allosteric modifiers.
Topics: Allosteric Regulation; Antisickling Agents; Benzyl Compounds; Bezafibrate; Carboxylic Acids; Clofibrate; Hemoglobin A; Humans; Myoglobin; Protein Binding; Protein Conformation; Solutions; Structure-Activity Relationship | 1990 |
Long-term effects of peroxisome proliferators on the balance between hydrogen peroxide-generating and scavenging capacities in the liver of Fischer-344 rats.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Cells, Cultured; Clofibrate; Cytosol; Diethylhexyl Phthalate; Enzyme Activation; Hydrogen Peroxide; Liver; Liver Neoplasms, Experimental; Male; Microbodies; Microscopy, Electron; Oxidoreductases; Phthalic Acids; Rats; Rats, Inbred F344; Time Factors | 1990 |
Altered radiosensitivity in a mouse carcinoma after administration of clofibrate and bezafibrate.
Topics: Animals; Bezafibrate; Carcinoma; Clofibrate; Mice; Oxyhemoglobins; Radiation Tolerance; Radiation-Sensitizing Agents | 1989 |
Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
Topics: Bezafibrate; Clofibrate; Coronary Disease; Fibrinogen; Humans; Hypertension; Male; Smoking; World Health Organization | 1989 |
Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Clofibric Acid; Fibric Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Male; Microsomes, Liver; Rats; Rats, Inbred Strains; Sterol O-Acyltransferase | 1989 |
Adipose conversion of cultured rat primary preadipocytes by hypolipidemic drugs.
Topics: Adipose Tissue; Animals; Bezafibrate; Bucladesine; Cell Differentiation; Cells, Cultured; Clofibrate; Cyclic AMP; Glycerolphosphate Dehydrogenase; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Male; Rats; Triglycerides | 1986 |
Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
Topics: Animals; Bezafibrate; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Cells, Cultured; Clofibrate; Clofibric Acid; Fatty Acids; Fibric Acids; Glucagon; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Rats; Rats, Inbred Strains | 1988 |
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates | 1986 |
Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
Topics: Administration, Oral; Animals; Bezafibrate; Carcinoid Tumor; Clofibrate; Clofibric Acid; Fibric Acids; Gastric Juice; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred F344; Species Specificity; Stomach Neoplasms; Time Factors | 1988 |
A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol, HDL; Clofibrate; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Phenols; Probucol | 1988 |
Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes.
Topics: Acyltransferases; Animals; Bezafibrate; Carnitine O-Palmitoyltransferase; Cells, Cultured; Clofibrate; Clofibric Acid; Epoxy Compounds; Ethers, Cyclic; Fatty Acids; Fibric Acids; Isoenzymes; Liver; Male; Rats; Rats, Inbred Strains; Time Factors; Triglycerides | 1988 |
The modification of hemoglobin affinity for oxygen and tumor radiosensitivity by antilipidemic drugs.
Topics: Animals; Bezafibrate; Clofibrate; Combined Modality Therapy; Gemfibrozil; Hemoglobins; Hypolipidemic Agents; Mice; Neoplasm Transplantation; Oxygen; Pentanoic Acids; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1987 |
Ethyl 2-([5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate as a new potent oxyisobutyrate hypolipidaemic with unusual features.
Topics: Animals; Bezafibrate; Chemical Phenomena; Chemistry; Cholesterol; Clofibrate; Diet; Hypercholesterolemia; Hypolipidemic Agents; Imidazoles; Lipoproteins, LDL; Male; Naphthalenes; Rats | 1987 |
Bezafibrate lowers oxygen affinity of haemoglobin.
Topics: 2,3-Diphosphoglycerate; Anemia, Sickle Cell; Bezafibrate; Clofibrate; Diphosphoglyceric Acids; Drug Synergism; Erythrocytes; Hemoglobin A; Hemoglobin, Sickle; Humans; Oxygen; Solubility | 1983 |
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
Topics: Adult; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Receptors, Cell Surface; Receptors, LDL | 1982 |
Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Topics: Animals; Anticholesteremic Agents; Bezafibrate; Caprylates; Carbon Radioisotopes; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Lovastatin; Male; Mevalonic Acid; Naphthalenes; Pentanoic Acids; Rats; Rats, Inbred F344; Sterols; Valerates | 1983 |
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides | 1983 |
[Improvement in diabetes control by treatment with bezafibrate].
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Insulin; Male; Sulfonylurea Compounds; Triglycerides | 1982 |
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides | 1981 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides | 1983 |
The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins.
Topics: Animals; Ascitic Fluid; Bezafibrate; Cholesterol Esters; Clofibrate; Clofibric Acid; Lipoproteins, LDL; Macrophages; Rabbits; Sterol Esterase; Sterol O-Acyltransferase | 1983 |
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Triglycerides | 1983 |
The short- and long-term effects of bezafibrate in the rat.
Topics: Animals; Bezafibrate; Carnitine O-Acetyltransferase; Catalase; Cholesterol; Clofibrate; Clofibric Acid; Female; Hypolipidemic Agents; Kinetics; Liver; Male; Microbodies; Microscopy, Electron; Organ Size; Organoids; Rats; Rats, Inbred Strains; Triglycerides | 1982 |
Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Esters; Fatty Acids; Female; Humans; Insulin; Lipids; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides | 1980 |
The effect of bezafibrate and clofibrate on cholesterol ester metabolism in 3T3 cells in smooth muscle cells in tissue culture.
Topics: Animals; Aorta; Bezafibrate; Cell Line; Cholesterol; Cholesterol Esters; Clofibrate; Clofibric Acid; Culture Techniques; Lipoproteins, LDL; Mice; Muscle, Smooth, Vascular; Swine | 1982 |
[Bezafibrate in primary hyperlipidemias (author's transl)].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Hyperlipoproteinemias; Lipoprotein Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged | 1982 |
Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
Topics: Apolipoprotein C-I; Apolipoprotein C-II; Apolipoproteins; Apolipoproteins C; Apolipoproteins E; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Protein Conformation; Triglycerides | 1982 |
Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat.
Topics: Animals; Bezafibrate; Cell Division; Cell Fractionation; Clofibrate; Clofibric Acid; Female; Hepatomegaly; Hypolipidemic Agents; Male; Microbodies; Organ Size; Organoids; Rats; Rats, Inbred F344; Sex Factors | 1982 |
Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Isoenzymes; Kidney; Male; Middle Aged; Muscle Proteins; Muscles; Myoglobinuria | 1982 |
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Muscles | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Infusions, Parenteral; Kidney Failure, Chronic; Lipids; Physical Exertion; Rats; Renal Dialysis | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipid Metabolism; Lipoproteins; Male; Triglycerides | 1982 |
Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Microbodies; Rats; Time Factors | 1982 |
The effect of bezafibrate and clofibrate on microsomal ACAT and lysosomal cholesterol ester hydrolase activity in the cholesterol-fed rabbit aorta.
Topics: Acyltransferases; Animals; Aorta; Bezafibrate; Carboxylic Ester Hydrolases; Clofibrate; Clofibric Acid; Female; Hypolipidemic Agents; Lysosomes; Rabbits; Regression Analysis; Sterol Esterase; Sterol O-Acyltransferase | 1982 |
[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 1982 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Placebos | 1981 |
"In vitro" metabolism of bezafibrate by rat liver.
Topics: Animals; Bezafibrate; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Hydroxylation; Hypolipidemic Agents; In Vitro Techniques; Kinetics; Liver; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Rats; Subcellular Fractions | 1981 |
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type IV; Lipids; Lipoproteins, HDL; Male; Middle Aged; Triglycerides | 1980 |
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Inositol; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nicotinic Acids; Nicotinyl Alcohol; Xanthinol Niacinate | 1980 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Triglycerides | 1980 |
Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
Topics: Alkaline Phosphatase; Animals; Bezafibrate; Bilirubin; Clofibrate; Clofibric Acid; Glucuronates; Glucuronosyltransferase; Hexosyltransferases; Hypolipidemic Agents; Liver; Male; Microsomes, Liver; Rats; Rats, Inbred Strains | 1981 |
[Rhabdomyolysis with acute renal failure due to bezafibrate].
Topics: Acute Kidney Injury; Bezafibrate; Clofibrate; Clofibric Acid; Humans; Male; Middle Aged; Muscular Diseases | 1981 |
Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
Topics: Adult; Bezafibrate; Cerebral Infarction; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Lipoproteins, HDL; Male; Middle Aged | 1981 |
Acute muscular syndrome after bezafibrate.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Humans; Hypolipidemic Agents; Myoglobinuria | 1981 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Kinetics; Male; Middle Aged | 1981 |
Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Topics: Administration, Oral; Adolescent; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Humans; Hypolipidemic Agents; Kinetics; Male | 1981 |
Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
Topics: Animals; Bezafibrate; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Hypolipidemic Agents; Liver; Male; Mixed Function Oxygenases; Oxidoreductases; Rats; Rats, Inbred Strains; Spectrum Analysis | 1981 |
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Kidney Diseases; Kinetics; Male; Middle Aged | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Lipoproteins, HDL; Triglycerides | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Inositol; Lipoproteins; Nicotinic Acids; Xanthinol Niacinate | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides | 1980 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged | 1980 |
Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation.
Topics: Acetyltransferases; Animals; Bezafibrate; Clofibrate; Dietary Fats; Fatty Acid Desaturases; Fatty Acid Elongases; Fatty Acids; Gemfibrozil; Male; Microbodies; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Time Factors | 1995 |
Inhibition of neutral cholesterol ester hydrolase in rat liver by fibric acids and probucol in vitro.
Topics: Animals; Bezafibrate; Clofibrate; Cytosol; Kinetics; Liver; Male; Microsomes, Liver; Probucol; Rats; Sterol Esterase | 1994 |
The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.
Topics: Animals; Bezafibrate; Body Weight; Cholesterol; Cholesterol Esters; Clofibrate; Cytosol; Liver; Male; Microsomes, Liver; Rats; Rats, Wistar; Sterol Esterase; Sterol O-Acyltransferase | 1994 |
Diverse mechanisms of calcium mobilization by peroxisome proliferators in rat hepatocytes.
Topics: Animals; Anticholesteremic Agents; Antifungal Agents; Bezafibrate; Calcium; Clofibrate; Homeostasis; Imidazoles; In Vitro Techniques; Liver; Male; Microbodies; Pyrimidines; Rats; Rats, Wistar | 1995 |
Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
Topics: Animals; Bezafibrate; Cholesterol; Clofibrate; Coenzyme A Ligases; Diet; Gemfibrozil; Hypolipidemic Agents; Lipids; Liver; Male; Microbodies; Organ Size; Palmitoyl-CoA Hydrolase; Rats; Rats, Sprague-Dawley; Repressor Proteins; Saccharomyces cerevisiae Proteins; Triglycerides | 1994 |
The effect of fibric acid derivatives on cholesterol metabolism in rat liver.
Topics: Animals; Bezafibrate; Cholesterol; Clofibrate; Liver; Male; Organ Size; Rats; Rats, Wistar; Sterol Esterase; Sterol O-Acyltransferase | 1994 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Regulation of xanthine dehydrogenase in rat liver in response to peroxisome proliferators.
Topics: Animals; Bezafibrate; Blotting, Western; Caprylates; Catalase; Clofibrate; Dehydroepiandrosterone; Diethylhexyl Phthalate; Fluorocarbons; Kinetics; Liver; Male; Microbodies; Rats; Rats, Wistar; Xanthine Dehydrogenase | 1993 |
Cooperative effect of inositol hexakisphosphate, bezafibrate, and clofibric acid on the spectroscopic properties of the nitric oxide derivative of ferrous human hemoglobin.
Topics: Bezafibrate; Clofibrate; Electron Spin Resonance Spectroscopy; Glycated Hemoglobin; Humans; Nitric Oxide; Phytic Acid; Spectrophotometry; Thermodynamics | 1993 |
Increase of adipose differentiation by hypolipidemic fibrate drugs in Ob 17 preadipocytes: requirement for thyroid hormones.
Topics: Adipose Tissue; Animals; Bezafibrate; Cell Differentiation; Cell Line; Cell Nucleus; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Mice; Mice, Obese; Receptors, Thyroid Hormone; Thyroid Hormones; Thyroxine | 1993 |
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S | 1996 |
Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats.
Topics: Animals; Bezafibrate; Cell Division; Clofibrate; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Gemfibrozil; Hypolipidemic Agents; Lipids; Liver; Male; Microbodies; Phosphatidylcholines; Phosphatidylethanolamines; Rats; Rats, Sprague-Dawley; Time Factors | 1995 |
Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs.
Topics: Animals; Bezafibrate; Clofibrate; Fatty Acid Synthases; Fatty Acids; Gemfibrozil; Guinea Pigs; Hypolipidemic Agents; Male; Microsomes, Liver; NADH Dehydrogenase; NADPH-Ferrihemoprotein Reductase; Palmitoyl-CoA Hydrolase; Phospholipids | 1995 |
Growth regulation by peroxisome proliferators: opposing activities in early and late G1.
Topics: Animals; Bezafibrate; Carcinogens; Cell Cycle; Cell Line; Clofibrate; Clofibric Acid; DNA; Fibric Acids; Gene Expression Regulation; Genes, Immediate-Early; Growth Substances; Mice; Microbodies; Pyrimidines; Signal Transduction; Time Factors; Transcriptional Activation | 1996 |
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides | 1995 |
Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
Topics: Animals; Antioxidants; Bezafibrate; Clofibrate; Copper Sulfate; Fatty Acids; Gemfibrozil; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley | 1996 |
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region.
Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays | 1996 |
Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.
Topics: Animals; Anticholesteremic Agents; Bezafibrate; Clofibrate; Cyclin-Dependent Kinases; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Female; Gemfibrozil; Isoenzymes; Liver; Male; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Organ Size; Oxidation-Reduction; Palmitoyl Coenzyme A; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred Strains; Sex Characteristics | 1997 |
Peroxisome proliferator activated receptors in Atlantic salmon (Salmo salar): effects on PPAR transcription and acyl-CoA oxidase activity in hepatocytes by peroxisome proliferators and fatty acids.
Topics: Acyl-CoA Oxidase; Animals; Base Sequence; Bezafibrate; Blotting, Northern; Clofibrate; DNA, Complementary; Fatty Acids; Humans; L-Lactate Dehydrogenase; Liver; Microbodies; Molecular Sequence Data; Oxidoreductases; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Salmon; Sequence Analysis, DNA; Sequence Homology; Transcription Factors; Transcription, Genetic | 1997 |
No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Bezafibrate; Cells, Cultured; Clofibrate; Clofibric Acid; Gemfibrozil; Humans; Liver; Macaca fascicularis | 1998 |
The effect of peroxisome proliferators on mitochondrial bioenergetics.
Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene | 1999 |
Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.
Topics: Animals; Bezafibrate; Carrier Proteins; Clofibrate; DNA-Binding Proteins; Eating; Fatty Acids, Nonesterified; Female; Gene Expression Regulation, Developmental; Hypolipidemic Agents; Ion Channels; Leptin; Male; Mice; Mitochondria, Muscle; Mitochondrial Proteins; Muscle Development; Muscle, Skeletal; Peroxisome Proliferators; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Uncoupling Protein 3 | 1999 |
Gallstones in patients with rheumatoid arthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bezafibrate; C-Reactive Protein; Cholelithiasis; Clofibrate; Creatine; Female; Gastrectomy; Humans; Hypolipidemic Agents; Incidence; Kidney Calculi; Male; Metabolic Clearance Rate; Middle Aged; Ultrasonography | 1999 |
Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study.
Topics: Bezafibrate; Clofibrate; Electron Spin Resonance Spectroscopy; Heme; Humans; Hypolipidemic Agents; Molecular Structure; Protein Binding; Protein Structure, Quaternary; Protein Structure, Tertiary; Serum Albumin | 2001 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer.
Topics: Acids, Acyclic; Animals; Bezafibrate; Binding Sites; Cell Line, Tumor; Cells, Cultured; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Dimerization; DNA-Binding Proteins; Gemfibrozil; Gene Expression Regulation; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Humans; Hydroxycholesterols; Ligands; Liver X Receptors; Nuclear Proteins; Orphan Nuclear Receptors; Promoter Regions, Genetic; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Repetitive Sequences, Nucleic Acid; Response Elements; Transcription Factors | 2004 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Synthesis of highly water-soluble fibrate derivatives via BGLation.
Topics: Animals; Bezafibrate; Clofibrate; Fenofibrate; Hypolipidemic Agents; Male; Rats; Rats, Sprague-Dawley; Solubility; Triglycerides; Water | 2012 |
Opposing Effects of PPARα Agonism and Antagonism on Refractive Development and Form Deprivation Myopia in Guinea Pigs.
Topics: Animals; Apolipoprotein A-II; Bezafibrate; Biometry; Blotting, Western; Butyrates; Clofibrate; Collagen Type I; Disease Models, Animal; Electroretinography; Fluorescent Antibody Technique, Indirect; Guinea Pigs; Intraocular Pressure; Malate Dehydrogenase; Myopia; Oxazoles; Phenylurea Compounds; PPAR alpha; Refraction, Ocular; Sensory Deprivation; Tyrosine | 2018 |
Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice.
Topics: Adenosine Triphosphate; Animals; Bezafibrate; Chromans; Clofibrate; Electron Transport Complex I; Fatty Acids; Humans; Leigh Disease; Longevity; Mice; Mice, Knockout; Mitochondria; Mitochondrial Diseases; Motor Activity; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors | 2020 |